FORT WORTH, Texas, July 15 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., , announced today the filing of a new 510K on a new wound management product utilizing their patented hydrolyzed collagen technology.
The new product (patent pending) will combine the hydrolyzed collagen with the healing properties of PSGAG (polysulfated glycosaminoglycan) and will initially be available in gel form. Hydrolyzed collagen with PSGAG wound gel is an absorbent hydrolyzed collagen for the management of exudative wounds. When interacting with wound fluid hydrolyzed collagen with PSGAG wound gel immediately begins to absorb wound exudates which may contain excess MMP’s thought to impair tissue regeneration. PSGAG has been shown in a porcine wound study to reduce the density of wound granulation tissue which in turn reduces resistance to epidermal migration.
Wound Care Innovations’ patented advanced wound care hydrolyzed collagen product, CellerateRx(R), is FDA cleared for acute and chronic wounds which include but are not limited to pressure ulcers (stage I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and 1st and 2nd degree burns. “We are very excited about the next generation product with our patented hydrolyzed collagen,” stated Cathy Bradshaw, President of Wound Care Innovations. “We believe that the addition of PSGAG will have an impact on the quality of wound granulation tissue facilitating epidermal regeneration and will provide clinicians with yet another distinctive product for difficult wounds.”
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company’s Website at www.Celleraterx.com .
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Compensation Disclaimer: Capital Pros Network CPN has been compensated the equivalent of $50,000 from WNDM.OB. Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by Capital Pros Network or WNDM.OB (the “Company”), as well as those contained herein, that are not historical facts are “forward- looking statements” within the meaning of Section 21E of the Securities and Exchange Act of 1934 and, because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
CONTACT: MEDIA: Mr. Jonathan Pappie, mrpappie@yahoo.com,
jpappie@capitalpros.com, +1-760-669-9521, Fax: +1-760-281-9130, for Wound
Management Technologies, Inc.
Web site: http://www.Celleraterx.com/
